The $300M shelf is a standard precautionary filing for a clinical-stage biotech with a $325M market cap. No immediate dilution risk — the company has $132.6M cash and explicitly states it is funded through Phase 2 readouts. Monitor for any prospectus supplement filing, which would signal an actual offering. The concurrent positive Phase 1b data and upcoming Phase 2 catalysts (UC IND in Q2 2026, Phase 2 start in Q3 2026) provide a potential positive narrative that could support the stock if no offering materializes.
Price Chart
Executive Summary
Palisade Bio filed a $300M universal shelf registration statement on Form S-3, concurrent with its Q1 2026 earnings release and 10-Q filing. The company reported $132.6M in cash as of March 31, 2026, with R&D expenses of $6.4M (up from $1.0M YoY) and a net loss of $9.6M. The shelf provides maximum flexibility for future capital raises, but the company states existing cash funds operations through key Phase 2 readouts in 2H 2027 and early 2028, suggesting this is an opportunistic shelf filing rather than an imminent dilutive event.
Key Financial Metrics
Key Facts
- Filed $300M universal shelf registration (S-3) on May 12, 2026
- Cash and cash equivalents of $132.6M as of March 31, 2026
- Q1 2026 R&D expenses of $6.4M vs $1.0M in Q1 2025 (up 540%)
- Q1 2026 net loss of $9.6M vs $2.4M in Q1 2025
- Company states cash on hand sufficient through Phase 2 UC readout (2H 2027) and Phase 2 CD readout (early 2028)
- Phase 2 UC trial initiation targeted for Q3 2026; IND submission expected Q2 2026
- Phase 1a/b for PALI-2108 completed with positive data in UC and fibrostenotic Crohn's disease
- Outstanding warrants to purchase ~13.95M shares at $2.45 weighted-average exercise price
- Pre-funded warrants to purchase ~43.87M shares at $0.0001 exercise price
- Stock price at filing: $1.94 per share (May 11, 2026)
Financial Impact
Up to $300M in potential future capital raises, but no immediate offering. Current cash burn rate ~$38.4M annualized (Q1 2026 operating expenses).
Risk Factors
- Shelf allows for up to $300M in future dilution at management's discretion
- Q1 2026 operating loss of $9.6M with R&D spend accelerating 5.4x YoY
- Pre-funded warrants (43.87M shares at $0.0001) represent significant overhang — exercisable at any time
- Phase 2 clinical risk — PALI-2108 has only been tested in 89 subjects across Phase 1
- No revenue and no approved products — entirely dependent on clinical success and capital markets
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 2 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| S-3 Filing (Primary) | 0001493152-26-022548 |
| Exhibit: ex4-5.htm | 0001493152-26-022548 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Aug 10, 2026 7w ago | 8-K | $2.14 $2.05 | ▼ −4.21% | ▼ −3.15% | $1.44 (−32.71%) |
Jul 10, 2026 11w ago | Insider Cluster | $1.89 $2.10 | ▲ +11.11% | ▲ +7.93% | $1.44 (−23.81%) |
Jul 8, 2026 12w ago | Insider Cluster | $1.97 $2.09 | ▲ +6.09% | ▲ +3.85% | $1.44 (−26.90%) |
Jun 11, 2026 16w ago | 8-K | $1.71 $1.96 | ▲ +14.62% | ▲ +12.84% | $1.44 (−15.79%) |
May 22, 2026 19w ago | EFFECT | $1.95 $1.89 | ▼ −3.08% | ▼ −1.66% | $1.44 (−26.15%) |
May 12, 2026 20w ago | S-3 | $1.87 $1.78 | ▼ −4.81% | ▼ −4.20% | $1.44 (−22.99%) |
Apr 29, 2026 22w ago | DEFA14A | $2.00 $2.12 | ▲ +6.00% | ▲ +0.77% | $1.44 (−28.00%) |
Apr 2, 2026 26w ago | 8-K | $1.89 $2.00 | ▲ +5.82% | ▼ −4.06% | $1.44 (−23.81%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access